An Oral Alternative to Injections
For years, effective treatment for many autoimmune conditions like rheumatoid arthritis meant injectable or infused biologic medications, which are highly effective but require injection or infusion and carry logistical burden. Janus kinase (JAK) inhibitors emerged as an oral alternative, pills that target specific intracellular signaling pathways involved in inflammatory immune responses, offering comparable effectiveness for many patients without the need for injections.
How They Work Differently
Rather than targeting a single inflammatory molecule from outside the cell like many biologics, JAK inhibitors work inside the cell to block signaling pathways that multiple inflammatory cytokines use to exert their effects, providing broader anti-inflammatory action through a different mechanism. This has proven effective across multiple autoimmune conditions including rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease, expanding options for patients who have not responded adequately to other treatments.
Safety Considerations Shaping Use
Post-approval safety studies identified increased risks of certain cardiovascular events, blood clots, and cancer with JAK inhibitors compared to some other treatments in specific patient populations, particularly older patients with cardiovascular risk factors, leading to more cautious, individualized prescribing guidance. This evolving safety picture illustrates how real-world use continues to refine understanding even after approval, ensuring the medications are used in patients where benefits clearly outweigh risks. Facilities can source pharmacy supplies and lab supplies from our catalog.
